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Effects of a b-blocker on the cardiovascular response
to MDMA (Ecstasy)
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ABSTRACT
Background MDMA (3,4-methylenedioxymethamph-
etamine, ‘Ecstasy’) produces tachycardia and
hypertension and is rarely associated with cardiovascular
and cerebrovascular complications. In clinical practice,
b-blockers are often withheld in patients with stimulant
intoxication because they may increase hypertension and
coronary artery vasospasm due to loss of b2-mediated
vasodilation and unopposed a-receptor activation.
However, it is unknown whether b-blockers affect the
cardiovascular response to MDMA.
Methods The effects of the non-selective b-blocker
pindolol (20 mg) on the cardiovascular effects of
MDMA (1.6 mg/kg) were investigated in a double-blind
placebo-controlled crossover study in 16 healthy
subjects.
Results Pindolol prevented MDMA-induced increases in
heart rate. Peak values (mean6SD) for heart rate
were 84613 beats/min after MDMA vs 6967 beats/min
after pindolol-MDMA. In contrast, pindolol pretreatment
had no effect on increases in mean arterial blood pressure
(MAP) after MDMA. Peak MAP values were
115611 mm Hg after MDMA vs 114611 mm Hg after
pindolol-MDMA. Pindolol did not change adverse effects
of MDMA.
Conclusion The results of this study indicate that
b-blockers may prevent increases in heart rate but not
hypertensive and adverse effects of MDMA.
INTRODUCTION
MDMA (3,4-Methylenedioxymethamphetamine)
is the main compound contained in ‘Ecstasy ’ pills.
Acute adverse effects of MDMA include hyper-
thermia leading to rhabdomyolysis and multiorgan
failure, hyponatraemic cerebral oedema, acute liver
failure, serotonin syndrome and acute panic reac-
tions.1 2 Rarely, MDMA has been associated with
vascular events such as myocardial infarction,
subarachnoid and intracranial haemorrhage and
cerebral infarction.3 4 These vascular complications
may arise from cardiostimulant and hypertensive
effects of MDMA.5 b-Adrenergic antagonists are
commonly used in the treatment of myocardial
ischaemia and hypertension. However, in the case
of intoxications with cocaine or other stimulants,
the use of b-blockers is controversial because b-
blockade is thought to worsen hypertension and
coronary artery vasospasm through unopposed a-
receptor activation.6e8 It is unknown
whetherdand, if so, howdb-blockers affect
cardiovascular responses to MDMA. We assessed
the effects of the non-selective b-blocker pindolol
on the haemodynamic effects of MDMA in healthy
subjects.
METHODS
Participants
The use of MDMA in healthy subjects was
authorised by the Swiss Federal Health Office.
Sixteen male volunteers (age 2564 years, range
20e36) were included in the study. Subjects were
recruited from University Hospital staff or were
students at the Medical School of the University of
Zurich. All volunteers provided written consent
after being informed about the aims and design of
the study and potential risks associated with
MDMA and pindolol use. Subjects were screened to
be physically and mentally healthy according to
medical history, physical examination, ECG and
blood analyses, and were screened by a structured
psychiatric interview based on a computerised
diagnostic expert system.9 Exclusion criteria were
personal or family histories of mental diagnostic
and statistical manual of mental disorders (DSM IV)
axis I disorders, hypertension, cardiovascular or
neurological disorders, use of medications and prior
illicit drug use (except tetrahydrocannabinol-
containing products) on more than five occasions.
All subjects engaged in regular physical exercise.
Apart from sporadic use of cannabis, one subject
reported a single previous experience with a hallu-
cinogenic drug (psilocybin), two subjects had
previously used both MDMA and a hallucinogen,
and seven subjects were drug-naïve. Subjective
(primary outcome) and neurocognitive results from
the present study have previously been reported.10
Here we present the previously unpublished
cardiovascular and adverse effects (secondary
outcomes) of the same study subjects10 with one
additional subject.
Study design and setting
A double-blind placebo-controlled single-dose
crossover design was used with four treatment
conditions (placeboeplacebo, pindololeplacebo,
placeboeMDMA or pindololeMDMA) and
a 2-week washout time between sessions. This
design has the main advantage that subjects act as
their own control. Treatment order was pseudo-
random and counterbalanced to avoid time order
effects. The duration of the trial for an individual
subject was 6e10 weeks. Placebo or pindolol was
given to the subjects at 09.00 h on each of the four
study days. Sixty minutes later MDMA or placebo
was administered. Blood pressure, heart rate and
body temperature were measured at 0, 30, 60, 90,
120, 150, 180, and 210 min after pindololeplacebo
administration (60, 30, 0, 30, 60, 90, 120 and
150 min after MDMAeplacebo administration).
Blood pressure and heart rate were registered by an
ERKA ambulatory blood pressure measuring system
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(ERKA.OS 90-2, Kallmeyer Medizintechnik GmbH, Bad Tölz,
Germany) in the non-dominant arm after a resting time of 5 min
with the volunteer sitting in an arm chair with the back
supported. Measures were taken once per time point. Between
measurements, subjects were allowed to engage in non-strenuous
activities such as reading, listening to music or walking around in
the testing room. Most of the time subjects were sitting in an
armchair or lying on a couch. Body temperature was measured
with an axillary thermometer (Terumo C202 Terumo Corp,
Tokyo, Japan). Acute adverse effects were assessed 135 min after
pindololeplacebo (75 min after MDMAeplacebo) administra-
tion by the List of Complaints.5 11 This scale consists of 66 items
yielding a total adverse effects score (non-weighted sum of the
item answers) reliably measuring physical and general discom-
fort. The scale has previously been shown to be sensitive to the
effects of pharmacological pretreatments on the adverse effects
of MDMA.12 13 Subjective and cognitive drug effects were
measured as reported elsewhere.10
Substances
(6)-MDMA hydrochloride (Lipomed, Arlesheim) was obtained
from the Swiss Federal Health Office. Subjects received MDMA
at a dose of 1.6 mg/kg (mean6SD dose 122614 mg). This dose of
MDMA corresponds to a typical recreational dose of Ecstasy and
produces robust psychological and physiological effects.5
Pindolol (Visken, Novartis Pharma, Basel, Switzerland) was used
in a dose of 20 mg. Pindolol is a non-selective b-blocker with
intrinsic activity and additional serotonergic 5HT1-receptor-
blocking properties. We selected pindolol for this study and a dose
of 20 mg because this dose produces approximately 40% brain
5-HT1A receptor occupancy,14 and we were also interested in the
role of 5-HT1 receptors in the mediation of the subjective effects
of MDMA based on behavioural studies in rats.15e17 Pindolol is
commonly used in doses of 5e30 mg per day divided into two
daily doses in the treatment of arterial hypertension. Thus,
a single dose of 20 mg of pindolol corresponds to a moderate to
high therapeutic dose. Pindolol pretreatment slightly attenuated
positive derealisation associated with MDMA and did not alter
MDMA-induced impairment of cognitive performance as
described in detail elsewhere.10
Data analysis
All analyses were performed with STATISTICA Version 6.0
(StatSoft Inc, Tulsa, USA). We determined the peak effect in the
150 min after MDMAeplacebo administration (time points
60e210 min) and the area under the curve (AUC) of the effects
versus time curve calculated by the trapezoidal rule for each
value (time points 60e210 min). These individual peak effects
and AUC values for each outcome variable were analysed by
one-way repeated measures analysis of variance (ANOVA)
with treatment condition (placeboeplacebo, pindololeplacebo,
placeboeMDMA and pindololeMDMA) as within-subject
factor. Post hoc comparisons were performed using Tukey tests
based on significant main effects of treatment condition in the
omnibus ANOVA. The absence of treatment order and carryover
effects was confirmed by ANOVAwith treatment order (1e4) as
within-subject factor. Treatment effects were also analysed over
time with two-way repeated measures ANOVA with treatment
condition and time as within-subject factors followed by Tukey
tests based on significant treatment by time interactions in the
omnibus ANOVA. We controlled for deviations from multivar-
iate normality using Mauchley tests of sphericity. Greenhouse
and Geisser corrections were used where necessary to adjust for
deviations from multivariate normality. These analyses yielded
similar results to those using peak and AUC values. The criterion
for significance was set at p<0.05. Mean arterial blood pressure
(MAP) was calculated from diastolic blood pressure (DBP) and
systolic blood pressure (SBP) using the following formula:
MAP¼DBP+(SBPDBP)/3. A decrease in MAP of 5 mm Hg was
considered clinically relevant and similar to the previously
reported one for the effects of citalopram on MDMA-induced
increases in blood pressure.12 A sample size of 15 achieves 97%
power to detect a difference of 5 between the null hypothesis
mean of 5 and the alternative hypothesis mean of 0 with
a known SD of the difference of 512 and with a significance level
(a) of 0.05 using a two-sided one-sample t test.
RESULTS
Cardiovascular effects and body temperature
The results are shown in figure 1. All 16 subjects completed all
four study sessions. ANOVA showed that the four treatment
conditions overall resulted in significantly different peak levels of
heart rate and MAP across sessions (main effects: F(3,45)¼28.7,
p<0.001; F(3,45)¼47.9, p<0.001; respectively). MDMA signifi-
cantly increased peak values for heart rate by (mean6SD)
15610 beats/min (p<0.01) compared with placebo. Pindolol
prevented the MDMA-induced increase in heart rate (p<0.001
for placeboeMDMA vs pindololeMDMA) but had no effect on
heart rate when given alone compared with placebo. MDMA
significantly increased peak MAP by 1668 compared with
placebo (p<0.001). Pindolol had no effect on the peak MAP
response to MDMA. The MDMA-induced increase in peak body
temperature (0.260.38C compared with placebo) was not
significant. Pindolol had no effect on MDMA-induced elevations
in body temperature.
Adverse effects
MDMA significantly increased acute adverse effects scores (main
effectof treatment:F(3,45)¼10.3, p<0.001, post hoc test: p<0.001
for MDMA vs placebo). The most frequently reported acute side
effects of MDMAwere impaired balance, lack of appetite, thirst,
feelings of restlessness or restless legs, difficulty concentrating and
feeling cold or warm. None of the subjects reported chest pain.
Pindolol did not change the adverse effects of MDMA.
DISCUSSION
The b-blocker pindolol prevented MDMA-induced tachycardia
but not hypertension or other adverse effects associated with
MDMA. Pindolol is an antagonist at central serotonin 5-HT1
receptors.14 As described in detail elsewhere,10 pindolol moder-
ately attenuated MDMA-induced increases in positive mood,
dreaminess, derealisation and mania-like experience, indicating
a possible role for serotonergic 5-HT1 receptors in the mediation
of these mood effects of MDMA. In contrast, pindolol had no
effect on MDMA-induced cognitive performance impairment.10
In addition, the effect of pindolol pretreatment on the subjective
response to MDMA was weak compared with that of the sero-
tonin uptake transporter blocker citalopram,12 18 which is
thought to block the interaction of MDMA with the serotonin
transporter so inhibits the release of serotonin from presynaptic
nerve terminals.
We are not aware of reports on the effects of b-blockers on the
haemodynamic effects of amphetamines including MDMA. The
b-blocker propranolol decreases heart rate19 20 and decreases20 or
increases19 blood pressure in patients with acute cocaine intoxi-
cation. In a placebo-controlled study, the a-b-blocker carvedilol
increased both heart rate and blood pressure in response to
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smoked cocaine when carvedilol was used at a low dose which
preferentially blocks b-receptors.21 At a higher dose, which blocks
both a- and b-receptors, carvedilol decreased all haemodynamic
effects of cocaine.21 The a-b-blocker labetolol, which has a
higher relative affinity for the a-receptor than carvedilol, dose-
dependently prevented all haemodynamic effects of smoked or
Figure 1 Graphs from left to right show
drug effects over time, peak values
(60e210 min) and area under the curve
values (AUC from 60 to 210 min3103).
(A) Pindolol pretreatment prevented the
MDMA-induced increase in heart rate.
(B) Pindolol had no effect on MDMA-
induced increases in mean arterial blood
pressure. (C) Pindolol had no effect on
the non-significant increase in body
temperature associated with MDMA. (D)
Pindolol did not change adverse effects
associated with MDMA. *p<0.05 and
***p<0.001 placebo-MDMA vs placebo-
placebo, yp<0.05 and yyyp<0.001
placebo-MDMA vs pindolol-MDMA.
Values represent mean6SE of 16
subjects.
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intranasal cocaine.6 22 Furthermore, propranolol, but not labe-
talol, potentiated cocaine-induced coronary vasoconstriction.6 7
Together these studies indicate that b-blockade without
a-blockade has no effect or may even increase cocaine-induced
hypertension, possibly due to unopposed a-receptor stimulation
and increased vasoconstriction. Our results extend these findings
and suggest that b-blockade affects MDMA-induced tachycardia
but does not influence the blood pressure and adverse effects of
MDMA. Severe MDMA toxicity such as multiorgan failure
results from hyperthermia and not solely from tachycardia.1
Heart rate is an easily determined marker of the severity of
MDMA poisoning and b-blockade may mask this MDMA effect,
during which time serious MDMA toxicity develops.
The present study has several limitations. Pindolol is
a non-selective b-receptor blocker with intrinsic activity, unlike
the b1-selective b-blockers that are mostly used today and that
may interact differently withMDMA. Pindolol was used because
this compound also blocks serotonergic 5-HT1 receptors and the
primary aim of this study was to investigate the role of 5-HT1 in
the subjective effects of MDMA in humans. This focus was also
the reason why pindolol was given before MDMA. Treatment
after MDMA would have more closely mirrored the clinical
situation where treatment for cardiovascular stimulation asso-
ciated with intoxication with Ecstasy would be initiated
following ingestion of MDMA. Treatment with a b-blocker after
MDMA administration may result in less effective blockade of
the effects of MDMA due to the delayed availability of the
blocker at the site of action, but is unlikely to result in a quali-
tatively different pharmacodynamic interaction. Only single
doses of pindolol and MDMA were used in the present study.
However, the significant interactive effects of pindolol and
MDMA on heart rate indicate that effective doses of both
compounds were used. Nevertheless, different doses could
interact differently. We do not know how the haemodynamic
changes observed in our study would translate into actual risk
changes for vascular complications. For example, the beneficial
effects of b-blockers on heart rate and cardiac oxygen consump-
tion may outweigh the potential harm of theoretically unop-
posed a-stimulation.23 Finally, the present study was performed
using pure MDMA in healthy subjects who were not engaged in
physical activities and were seated in a quiet research environ-
ment. In contrast, recreational users of MDMA may be dancing
and are likely to ingest other substances in addition to MDMA
including cocaine or other amphetamines and may also show
significant co-morbidity.2 The findings from this study can
therefore not be generalised to the treatment of patients with
cardiovascular complications associated with recreational
MDMA use. Nevertheless, our results indicate that b-blockers
would not be expected to worsen the cardiovascular and adverse
effects of MDMA. In addition, subjects on b-blocker medication
are likely to show similar blood pressure responses to MDMA as
those without medication.
In conclusion, b-blockers may prevent tachycardia but not
blood pressure responses or adverse effects associated with
MDMA. The role of a-b-blockade in the treatment of MDMA
intoxications needs further evaluation. Furthermore, MDMA
stimulates the sympathetic nervous system centrally rather than
peripherally,1 24 25 so centrally-acting sedative agents (eg,
benzodiazepines) should be used as first-line treatments in cases
of MDMA or other stimulant intoxication.1 26 27
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